FloridaMarijuana.net

AUGUST 16, 2018

Dementia cannot be confirmed until a patient is deceased. Dementia is hard on the patient, and often harder on the family or caregivers. Pharmaceutical treatments for for Dementia often only target symptoms like pain or depression, but those medicines do not cure or prevent the disease. 9-tetrahydrocannabinol (?9-THC)

Clinical Trials 184

Clinical Trials Marijuana Patients Pharmaceutical 184

Cannabis Law Report

JUNE 1, 2021

The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. billion, servicing nearly 340,000 active patients.

Clinical Trials 89

Clinical Trials Chronic Pain Data Research and Development 89

Cannabis Law Report

JUNE 17, 2021

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) raised its full-year 2021 financial guidance based on the acquisition of GW Pharmaceuticals, which was bought on May 5, 2021. As part of our continued R&D efforts we also look forward to advancing our PTSD and essential tremor programs, the nabiximols clinical trial program to support a U.S.

Pharmaceutical 83

Pharmaceutical Clinical Trials Therapy Programs 83

FloridaMarijuana.net

AUGUST 9, 2018

Because there is limited or conflicting research about “the true nature of traumatic brain injury and how it causes chronic degenerative problems,” treatment can be a challenging process for many patients. This means that often pharmaceutical medications are experimental.

Marijuana 190

Marijuana Patients Clinical Trials Treatment 190

Cannabis Law Report

AUGUST 17, 2021

reduction in 28-day seizure frequency relative to baseline in tuberous sclerosis complex (TSC) patients (n=23). Secondary endpoint of 50% responder rate at 30.4%, consistent with the Marigold Phase 3 CDKL5 deficiency disorder trial results. reduction was observed in focal seizures (n=19), the most common seizure type in TSC patients.

Pharmaceutical 76

Pharmaceutical Clinical Trials Treatment Patients 76

CannaTech

SEPTEMBER 23, 2019

The acceptance of medical cannabis by clinicians, researchers and government bodies is fairly universal, and patients have benefited from widespread access to full-spectrum cannabis in flower and oil form. Israel’s approach to cannabis has contributed to reducing stigma and increasing access for patients around the world.

Patients 79

Patients Policy Clinical Trials Research and Development 79

The Cannigma

FEBRUARY 1, 2023

Patients are often left to their own devices when looking into cannabis and cancer, given the lack of clinical evidence, and stigma surrounding the use of the plant as medicine. To date, very few human clinical trials have been conducted to assess the effectiveness of THC or CBD in treating cancer. The answer: Maybe!

Clinical Trials 145

Clinical Trials Research and Development Therapy Cannabinoids 145

Cannabis Law Report

DECEMBER 23, 2021

DUBLIN–(BUSINESS WIRE)– “The Pharmaceutical Cannabis Report: 2nd Edition” report has been added to ResearchAndMarkets.com’s offering. In both Europe and the United States, the sales of unapproved cannabis products such as smokable flower and full spectrum oils dwarf those of approved pharmaceuticals.

Pharmaceutical 74

Pharmaceutical Clinical Trials Research and Development Cannabinoids 74

Veriheal

FEBRUARY 11, 2021

Cannabis has been identified as a potentially effective strategy to decrease opiate usage and the survey wanted to determine how the use of medical cannabis affects opioid prescription usage among patients with chronic pain. They conducted an online survey of patients from three medical practice sites.

Chronic Pain 93

Chronic Pain Patients Clinical Trials Treatment 93

Cannabis Law Report

MARCH 30, 2019

The trials, to be tightly controlled in a hospital environment, are exempted from Japan’s Cannabis Control Act, which bans cannabis compounds generally. Epidiolex, manufactured by UK-based GW Pharmaceutical, was approved by the U.S. Japanese officials approve Epidiolex for clinical trials.

Clinical Trials 45

Clinical Trials Research and Development Epilepsy Environment 45

The Cannigma

JUNE 14, 2021

All that is about to change, thanks to a change at the DEA , which cultivators and industry experts say will be monumental for cannabis research, medical marijuana patients, and potentially the broader legal status of the plant itself. “We Junk’ cannabis ‘ill-suited for clinical trials’. Shutterstock).

DEA 133

DEA Research and Development Clinical Trials Pharmaceutical 133

Cannabis Law Report

JULY 7, 2021

Company plans to initiate Phase II trial with a leading academic institution. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Current TNF-a inhibitors available today, while effective, come with an array of adverse effects and concerns for patients,” said Adam Kaplin, M.D., About MyMD Pharmaceuticals, Inc.

Pharmaceutical 81

Pharmaceutical Data Clinical Trials Research and Development 81

NewsMunchies

DECEMBER 13, 2021

In the largest clinical trial to date, a new study conducted by the UK-based pharmaceutical company Compass Pathways shows that psilocybin or “magic” mushrooms can safely relieve depression. The trial included 233 patients from 10 countries in North America and Europe. Food and Drug Administration.

Clinical Trials 95

Clinical Trials Therapy Decriminalization Patients 95

Cannabis Law Report

OCTOBER 26, 2021

Incannex Healthcare Limited (ASX: IHL) has engaged pharmaceutical manufacturing company Procaps S.A The agreement between the two companies will see Procaps making IHL-42X for Incannex’s Phase 2, Phase 3, and open-label clinical trials. to develop and manufacture soft gel capsules of Incannex’s cannabis medicine IHL-42X.

Clinical Trials 52

Clinical Trials Sleep Medicine Pharmaceutical 52

Cannabis Law Report

AUGUST 24, 2021

BALTIMORE–(BUSINESS WIRE)– $MYMD — MyMD Pharmaceuticals, Inc. Thus, there is a great need to develop new and effective therapeutics for treating patients. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 75

Pharmaceutical Clinical Trials Chronic Pain CBD 75

Puff Puff Post

MARCH 10, 2020

SOURCE InMed Pharmaceuticals Inc. InMed has conducted preclinical pharmacology studies that suggest CBN in INM-755 may help relieve hallmark EB symptoms, including inflammation and pain, as well potentially restore the integrity of the skin in a subset of EB Simplex patients. For more information, visit www.inmedpharma.com.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

AUGUST 7, 2021

The results of our successful pivotal Phase 3 clinical trial were recently published in Nature Medicine and profiled on the front page of The New York Times. We are pioneering a new kind of pharmaceutical company that prioritizes public benefit and is committed to sustainability, accountability, and transparency.

Clinical Trials 105

Clinical Trials Research and Development Compliance Compliance 105

Cannabis Law Report

APRIL 28, 2023

(“Biomind Labs” or the “Company”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological disorders by targeting the drivers of disease, is pleased to announce that it has commenced a Phase II clinical trial for its proprietary […] (..)

Clinical Trials 52

Clinical Trials Pharmaceutical Patients Business 52

Otherside Farms

JANUARY 24, 2019

In San Francisco and New York City, the physician-led pediatric studies will assess the viability of a purified cannabidiol as an anti-seizure treatment among patients with various forms of epilepsy. Although both studies will enroll 25 patients initially, the U.S. Cilio will also conduct two individual studies of the drug.

Clinical Trials 45

Clinical Trials Epilepsy Marijuana Pharmaceutical 45

Project CBD

MAY 3, 2023

Dr. Goldstein has treated thousands of patients with medical cannabis. She is the medical director of Canna-Centers Wellness & Education and the clinical advisor to Cannformatics. Remember, the pharmaceutical model is “this medicine addresses this specific target.” I have used it in some of my patients with autism.

Cannabinoids 209

Cannabinoids Sleep Clinical Trials CBD 209

FloridaMarijuana.net

AUGUST 13, 2018

There are a variety of treatment options to help patients cope with and heal from anxiety disorders. Pharmaceuticals come with side effects, though, and may vary from person-to-person. Medical marijuana is another option for patients suffering from anxiety. Medications can be used along with therapy.

Marijuana 145

Marijuana Patients Clinical Trials Conditions 145

Veriheal

JUNE 29, 2021

This Act permits individuals that have been diagnosed with life-threatening conditions or diseases that have exhausted all other approved treatment and therapeutic options that are also unable to participate in clinical trials the ability to access certain treatments that would otherwise be unapproved for access. A Push by Patients.

Therapy 64

Therapy DEA Patients Clinical Trials 64

The Cannigma

SEPTEMBER 21, 2021

There are cannabis users, patients, and just everyday fans who may be fans, but don’t make it a big part of their public persona. For these famous medical cannabis patients and supporters, it is something that can improve quality of life and which should be made readily available to anyone in need. 1) Patrick Stewart. It’s tricky.”.

Patients 96

Patients Research and Development Sleep Clinical Trials 96

MGC Pharma

FEBRUARY 20, 2018

The Top Medical Cannabis Research of 2017 A word from Ron Lipsky, Manager of Business Development and International Relations at MGC Pharmaceuticals MGC Pharma is still riding off the success of 2017 as we progress into 2018, with many exciting developments on the horizon.

Research and Development 100

Research and Development Clinical Trials Patients Chronic Pain 100

Puff Puff Post

NOVEMBER 5, 2019

5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers.

Clinical Trials 40

Clinical Trials Pharmaceutical Cannabinoids Data 40

Puff Puff Post

NOVEMBER 5, 2019

5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers.

Clinical Trials 8

Clinical Trials Pharmaceutical Cannabinoids Data 8

Cannabis Law Report

JUNE 21, 2021

Pharmaceutical companies use artificial intelligence (AI) to sort through reams of scientific data to find potentially effective active ingredients to be developed into approved drugs. The most recent one , from June 2021, takes a look at patients using cannabis to relieve pain. The report further breaks down use by specific cultivars.

Data 105

Data Clinical Trials Research and Development Indica 105

The Joint Blog

NOVEMBER 24, 2018

Fibromyalgia patients suffering from lower back pain respond favorably to medical cannabis as a treatment, according to a new study published in the journal Clinical and Experimental Rheumatology , and epublished by the National Institute of Health.

Patients 54

Patients Clinical Trials Treatment Marijuana 54

Cannabis Law Report

AUGUST 2, 2021

OTCQB: SPRCY ) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced positive top-line results for its proprietary compound, SCI-160 in a controlled pre-clinical trial on neuropathic and post-operative pain. TEL AVIV, Israel , Aug.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. What about other medical cannabis products? ” Source BBC: [link]. PDF Version.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Canna Care Docs

JUNE 22, 2018

An Introductory Lesson on THC Basics For Medical Cannabis Patients. Cannabis, a plant that has proven to be endlessly complex is still under the microscope by researchers, patients, physicians, and society. But many new patients need an introduction on THC basics, learning how it plays a role in a patient’s well-being and healing.

THC 66

THC Patients Blood Pressure Clinical Trials 66

Cannabis Law Report

DECEMBER 9, 2021

08, 2021 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. The Company believes it has produced a sufficient supply of cGMP DMT to complete its planned Phase 1 and Phase 2 clinical trials. as medical consultants to the Company’s DMT stroke clinical research program. Moreau CEO of Algernon Pharmaceuticals Inc. “We

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Canna Care Docs

OCTOBER 3, 2023

On top of overwhelming struggles or feelings, patients who have been diagnosed with a terminal illness can face a broad range of both physical and psychological effects. However, many of these pharmaceutical medications can just induce more unpleasant, debilitating effects on those who are ill.

Chronic Pain 105

Chronic Pain Clinical Trials Patients Cannabinoids 105

MedicalJane

OCTOBER 3, 2019

The United States Department of Defense and GW Pharmaceuticals are collaborating on a new clinical trial at the Montefiore Medical Center in New York. Dr. Eric Hollander, the Director of the Autism and Obsessive Compulsive Spectrum Program and Anxiety and Depression Program at Montefiore Hospital, is leading the clinical trial.

Clinical Trials 74

Clinical Trials Epilepsy Pharmaceutical Treatment 74

Cannabis Law Report

JULY 12, 2019

Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. No hepatic side effects were noted.

Extraction 73

Extraction Pharmaceutical CBD Epilepsy 73

Cannabis Law Report

OCTOBER 6, 2021

Flora Pharma will seek to identify scientific gaps in the cannabis industry and ultimately work to translate that to pharmaceutical cannabis products backed by data. The immediate next steps are to submit data for ethics committee review and approval whereupon acceptance, further details will be provided. “A

Clinical Trials 40

Clinical Trials Research and Development Pharmaceutical Events 40

Veriheal

OCTOBER 13, 2020

Elevated levels of stress can even land these individuals in more discomfort, with IBD patients risking hospitalization due to inflammation. Factors such as diet and stress are known to aggravate IBD patients, but they do not cause it. . What is IBS? What is the Difference Between IBD and IBS?

Digestion 124

Digestion Treatment Conditions Research and Development 124